Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility
Reviews on circulating biomarkers in breast cancer usually focus on one single biomarker or a selective group of biomarkers. An overview summarizing the discovery and evaluation of all blood-based biomarkers in metastatic breast cancer is lacking. This systematic review aims to identify the availabl...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-02-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/18/2/363 |
id |
doaj-f4a5fe9b9d6748c5acb84a9355246d83 |
---|---|
record_format |
Article |
spelling |
doaj-f4a5fe9b9d6748c5acb84a9355246d832020-11-24T21:49:47ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-02-0118236310.3390/ijms18020363ijms18020363Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical UtilityA. M. Sofie Berghuis0Hendrik Koffijberg1Jai Prakash2Leon W. M. M. Terstappen3Maarten J. IJzerman4Health Technology and Services Research, University of Twente, Enschede 7500 AE, The NetherlandsHealth Technology and Services Research, University of Twente, Enschede 7500 AE, The NetherlandsBiomaterials Science and Technology, University of Twente, Enschede 7500 AE, The NetherlandsMedical Cell Biophysics, University of Twente, Enschede 7500 AE, The NetherlandsHealth Technology and Services Research, University of Twente, Enschede 7500 AE, The NetherlandsReviews on circulating biomarkers in breast cancer usually focus on one single biomarker or a selective group of biomarkers. An overview summarizing the discovery and evaluation of all blood-based biomarkers in metastatic breast cancer is lacking. This systematic review aims to identify the available evidence of known blood-based biomarkers in metastatic breast cancer, regarding their clinical utility and state-of-the-art position in the validation process. The initial search yielded 1078 original studies, of which 420 were assessed for eligibility. A total of 320 studies were included in the final synthesis. A Development, Evaluation and Application Chart (DEAC) of all biomarkers was developed. Most studies focus on identifying new biomarkers and search for relations between these biomarkers and traditional molecular characteristics. Biomarkers are usually investigated in only one study (68.8%). Only 9.8% of all biomarkers was investigated in more than five studies. Circulating tumor cells, gene expression within tumor cells and the concentration of secreted proteins are the most frequently investigated biomarkers in liquid biopsies. However, there is a lack of studies focusing on identifying the clinical utility of these biomarkers, by which the additional value still seems to be limited according to the investigated evidence.http://www.mdpi.com/1422-0067/18/2/363metastatic breast cancerliquid biopsycirculating biomarkersblood-based biomarkerscirculating tumor cells (CTCs)utilitydevelopmental stagesdevelopment evaluation and application chart (DEAC) |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
A. M. Sofie Berghuis Hendrik Koffijberg Jai Prakash Leon W. M. M. Terstappen Maarten J. IJzerman |
spellingShingle |
A. M. Sofie Berghuis Hendrik Koffijberg Jai Prakash Leon W. M. M. Terstappen Maarten J. IJzerman Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility International Journal of Molecular Sciences metastatic breast cancer liquid biopsy circulating biomarkers blood-based biomarkers circulating tumor cells (CTCs) utility developmental stages development evaluation and application chart (DEAC) |
author_facet |
A. M. Sofie Berghuis Hendrik Koffijberg Jai Prakash Leon W. M. M. Terstappen Maarten J. IJzerman |
author_sort |
A. M. Sofie Berghuis |
title |
Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility |
title_short |
Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility |
title_full |
Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility |
title_fullStr |
Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility |
title_full_unstemmed |
Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility |
title_sort |
detecting blood-based biomarkers in metastatic breast cancer: a systematic review of their current status and clinical utility |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1422-0067 |
publishDate |
2017-02-01 |
description |
Reviews on circulating biomarkers in breast cancer usually focus on one single biomarker or a selective group of biomarkers. An overview summarizing the discovery and evaluation of all blood-based biomarkers in metastatic breast cancer is lacking. This systematic review aims to identify the available evidence of known blood-based biomarkers in metastatic breast cancer, regarding their clinical utility and state-of-the-art position in the validation process. The initial search yielded 1078 original studies, of which 420 were assessed for eligibility. A total of 320 studies were included in the final synthesis. A Development, Evaluation and Application Chart (DEAC) of all biomarkers was developed. Most studies focus on identifying new biomarkers and search for relations between these biomarkers and traditional molecular characteristics. Biomarkers are usually investigated in only one study (68.8%). Only 9.8% of all biomarkers was investigated in more than five studies. Circulating tumor cells, gene expression within tumor cells and the concentration of secreted proteins are the most frequently investigated biomarkers in liquid biopsies. However, there is a lack of studies focusing on identifying the clinical utility of these biomarkers, by which the additional value still seems to be limited according to the investigated evidence. |
topic |
metastatic breast cancer liquid biopsy circulating biomarkers blood-based biomarkers circulating tumor cells (CTCs) utility developmental stages development evaluation and application chart (DEAC) |
url |
http://www.mdpi.com/1422-0067/18/2/363 |
work_keys_str_mv |
AT amsofieberghuis detectingbloodbasedbiomarkersinmetastaticbreastcancerasystematicreviewoftheircurrentstatusandclinicalutility AT hendrikkoffijberg detectingbloodbasedbiomarkersinmetastaticbreastcancerasystematicreviewoftheircurrentstatusandclinicalutility AT jaiprakash detectingbloodbasedbiomarkersinmetastaticbreastcancerasystematicreviewoftheircurrentstatusandclinicalutility AT leonwmmterstappen detectingbloodbasedbiomarkersinmetastaticbreastcancerasystematicreviewoftheircurrentstatusandclinicalutility AT maartenjijzerman detectingbloodbasedbiomarkersinmetastaticbreastcancerasystematicreviewoftheircurrentstatusandclinicalutility |
_version_ |
1725887428778000384 |